These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 25374101)

  • 21. Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama.
    Villarreal AE; Grajales S; O'Bryant SE; Edwards M; López L; Montalván A; Britton GB;
    J Alzheimers Dis; 2016 Oct; 54(3):897-901. PubMed ID: 27567849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
    Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
    J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.
    Hanson AJ; Bayer JL; Baker LD; Cholerton B; VanFossen B; Trittschuh E; Rissman RA; Donohue MC; Moghadam SH; Plymate SR; Craft S
    J Alzheimers Dis; 2015; 48(1):205-18. PubMed ID: 26401941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apolipoprotein E genotype and cerebrovascular alterations can influence conversion to dementia in patients with mild cognitive impairment.
    Viticchi G; Falsetti L; Vernieri F; Altamura C; Altavilla R; Luzzi S; Bartolini M; Provinciali L; Silvestrini M
    J Alzheimers Dis; 2014; 41(2):401-10. PubMed ID: 24625799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.
    Ouk M; Wu CY; Rabin JS; Jackson A; Edwards JD; Ramirez J; Masellis M; Swartz RH; Herrmann N; Lanctôt KL; Black SE; Swardfager W
    Alzheimers Res Ther; 2021 Feb; 13(1):43. PubMed ID: 33573702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropsychological measures predict decline to Alzheimer's dementia from mild cognitive impairment.
    Summers MJ; Saunders NL
    Neuropsychology; 2012 Jul; 26(4):498-508. PubMed ID: 22612573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.
    McIntyre RS; Soczynska JK; Woldeyohannes HO; Miranda A; Vaccarino A; Macqueen G; Lewis GF; Kennedy SH
    Bipolar Disord; 2012 Nov; 14(7):697-706. PubMed ID: 23107220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study.
    Brainerd CJ; Reyna VF; Petersen RC; Smith GE; Taub ES
    Neuropsychology; 2011 Nov; 25(6):679-89. PubMed ID: 21728427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal insulin improves memory in humans: superiority of insulin aspart.
    Benedict C; Hallschmid M; Schmitz K; Schultes B; Ratter F; Fehm HL; Born J; Kern W
    Neuropsychopharmacology; 2007 Jan; 32(1):239-43. PubMed ID: 16936707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
    Kennelly S; Abdullah L; Kenny RA; Mathura V; Luis CA; Mouzon B; Crawford F; Mullan M; Lawlor B
    Int J Geriatr Psychiatry; 2012 Apr; 27(4):415-22. PubMed ID: 21560164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Apolipoprotein E4 on the Driving Behavior of Patients with Amnestic Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia.
    Stanitsa E; Economou A; Beratis I; Kontaxopoulou D; Fragkiadaki S; Papastefanopoulou V; Pavlou D; Papantoniou P; Kroupis C; Papatriantafyllou J; Stefanis L; Yannis G; Papageorgiou SG
    J Alzheimers Dis; 2021; 84(3):1005-1014. PubMed ID: 34602476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease.
    Morgen K; Frölich L; Tost H; Plichta MM; Kölsch H; Rakebrandt F; Rienhoff O; Jessen F; Peters O; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Hampel H; Teipel SJ; Pantel J; Heuser I; Wiltfang J; Rüther E; Kornhuber J; Maier W; Meyer-Lindenberg A
    J Alzheimers Dis; 2013; 37(2):389-401. PubMed ID: 23948881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
    Morimoto BH; Schmechel D; Hirman J; Blackwell A; Keith J; Gold M;
    Dement Geriatr Cogn Disord; 2013; 35(5-6):325-36. PubMed ID: 23594991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease.
    Mustapic M; Tran J; Craft S; Kapogiannis D
    J Alzheimers Dis; 2019; 69(2):489-498. PubMed ID: 30958348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal Insulin for Alzheimer's Disease.
    Hallschmid M
    CNS Drugs; 2021 Jan; 35(1):21-37. PubMed ID: 33515428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
    Baker LD; Barsness SM; Borson S; Merriam GR; Friedman SD; Craft S; Vitiello MV
    Arch Neurol; 2012 Nov; 69(11):1420-9. PubMed ID: 22869065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.